Navigation Links
Biomoda Appoints Three Business Leaders to Board of Directors

New members will help commercialize innovative technologies for early lung

cancer detection

ALBUQUERQUE, N.M., May 5 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (, a development stage medical diagnostics company, today announced the election of three business leaders, Maria Zannes, David Lambros, and Lewis White, to its Board of Directors. The Board Members' terms as Directors began May 1.

"We are pleased to engage these leaders' keen business expertise and apply their high levels of practical and regulatory experience in the interests of Biomoda shareholders," said John Cousins, Biomoda president. "With their involvement, Biomoda is in an ideal position to influence the future of technology for early diagnosis and treatment of lung cancer throughout the world."

-- Maria Zannes brings more than 25 years of experience in the

environmental and energy industry -- from federal lobbyist to company

president. Formerly the president of the national waste-to-energy

trade group in Washington, D.C., Zannes currently consults for private

clients in the medical and waste industry. She was a legislative aide

and press secretary to Congressman Charles Wilson (D-Texas) after

leaving her home state of New Mexico where she began her career as a

journalist. Zannes is licensed to practice law in Washington State and

will be sworn into practice in New Mexico this summer

-- David Lambros was the elected law director of Brook Park, Ohio, and

presently serves the law director of the Village of Valley View and

the Village of Kelleys Island, Ohio. As law director, he served as the

chief legal counsel to cities negotiating with corporations and

business, and is an expert in municipal law. Lambros has practiced law

for more than 25 years and served on various boards, including

Commerce Exchange Bank and Southwest General Hospital. As a board

member of Commerce Exchange Bank, he was instrumental in raising share

value of the stock from $2.00 to a sale price of $13.00. He presently

is a director on the Systems Board at Southwest General Hospital, a

multi-million dollar company.

-- Lewis White, a major shareholder in Biomoda, is director and CEO of

New Energies Nebraska, LLC, a subsidiary of Standard Alcohol Company.

He has also served as CEO of Los Hojas Corporation and owned a

successful childcare business for 20 years, which he followed with an

interest in business investment through real estate and a thriving

food services business catering to niche markets. White attended the

University of Nebraska at Omaha where majored in Business

Administration and worked for the State of Nebraska.

With Biomoda's technology, clinicians can identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected under a microscope. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease at more advanced stages. Biomoda's technology complements these tools by screening for signs of lung cancer at an earlier stage, ensuring that patients receive advanced tests at the appropriate time.

Earlier this year, Biomoda and the New Mexico Institute of Mining and Technology announced their partnership with the New Mexico Department of Veterans Services to conduct a $350,000 clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the state's veterans. The New Mexico state legislature recently allocated an additional $1.3 million in funding through the Interim Tobacco Settlement Committee to the clinical screening program.

Lung cancer claims more lives than any other cancer. The expected five-year survival rate for all patients diagnosed with lung cancer is 15 percent; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16 percent of lung cancer cases are diagnosed at this early stage.
Biomoda's technology was originally developed at Los Alamos National


For more information contact:

John Cousins

Biomoda, Inc.


Forward-Looking Statement

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Biomoda's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. Biomoda, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Biomoda's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Announces Upcoming Interview With CEO of Biomoda
2. Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
3. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
4. Biomoda Announces Collaborative Agreement With New Mexico Tech
5. Biomoda Hires Senior Scientist to Expand Research & Development Effort
6. Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans
7. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
8. Codexis Appoints Singapore Laboratories Managing Director
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):